Website
News25/Ratings11
News · 26 weeks49-67%
2025-10-262026-04-19
Mix3590d
- Insider13(37%)
- SEC Filings10(29%)
- Other6(17%)
- Offering4(11%)
- Earnings1(3%)
- Leadership1(3%)
Latest news
25 items- SECSEC Form DEFA14A filed by Vaxcyte Inc.DEFA14A - Vaxcyte, Inc. (0001649094) (Filer)
- SECSEC Form DEF 14A filed by Vaxcyte Inc.DEF 14A - Vaxcyte, Inc. (0001649094) (Filer)
- INSIDERSEC Form 4 filed by Cowan Elvia4 - Vaxcyte, Inc. (0001649094) (Issuer)
- PRVaxcyte to Present at the 25th Annual Needham Virtual Healthcare ConferenceSAN CARLOS, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026 at 2:15 p.m. ET / 11:15 a.m. PT. A live webcast of the fireside chat can be accessed through the Investors & Media section of the Company's website at http://investors.vaxcyte.com. A replay of the webcast will be available for approximately 30 days following the conference. About Vaxcyte Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences
- INSIDERSEC Form 4 filed by Wassil Jim4 - Vaxcyte, Inc. (0001649094) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Vaxcyte Inc.SCHEDULE 13G/A - Vaxcyte, Inc. (0001649094) (Subject)
- PRVera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal OfficerBRISBANE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Jane Wright-Mitchell, Pharm.D., J.D., as Chief Legal Officer, effective immediately. "Jane has worked with Vera Therapeutics previously as a strategic legal consultant and brings a depth and breadth of experience in supporting companies through regulatory approvals, commercialization, and intellectual property management," said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics. "As we near the potential launch of
- PRVaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in AdultsOPUS-1 Phase 3 Study Designed to Establish a New Standard for Adult Pneumococcal Conjugate Vaccines (PCVs) Through Head-to-Head Safety, Tolerability and Immunogenicity Comparisons of VAX-31 with Capvaxive® (PCV21) and Prevnar 20® (PCV20), the Current Standard-of-Care PCVs Topline Safety, Tolerability and Immunogenicity Data from OPUS-1 Phase 3 Study Expected in Fourth Quarter of 2026 OPUS-2 Phase 3 Study Evaluating Concomitant Administration of VAX-31 and Seasonal Influenza Vaccine Designed to Provide Real-World Performance Insights in Adults; Results Expected in First Half of 2027 OPUS-3 Phase 3 Study Enrollment Ongoing in Adults Previously Vaccinated with Pneumococcal Vaccines; Results
- PRPositive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte's 31-Valent Pneumococcal Conjugate Vaccine (PCV) CandidateBased on the Strength of Unprecedented Results from the Positive Phase 1/2 Study in Adults Aged 50 and Older, Vaxcyte Advanced VAX-31 High Dose into Comprehensive Phase 3 Adult Program; Topline Data from the OPUS-1 Pivotal Noninferiority Trial Expected in the Fourth Quarter of 2026 At All Doses Studied, VAX-31 Demonstrated Robust Opsonophagocytic Activity and Immunoglobulin G Immune Responses for All 31 Serotypes and Was Observed to be Well Tolerated with a Safety Profile Similar to Prevnar 20® Results Further Validate Potential of Vaxcyte's Carrier-Sparing Platform to Deliver Broadest-Spectrum PCV Candidates that Provide Protection Against Both Currently Circulating and Historically Preva
- INSIDERSEC Form 4 filed by Cowan Elvia4 - Vaxcyte, Inc. (0001649094) (Issuer)
- INSIDERSEC Form 4 filed by Vaxcyte Inc.4 - Vaxcyte, Inc. (0001649094) (Issuer)
- INSIDERCHIEF EXECUTIVE OFFICER Pickering Grant covered exercise/tax liability with 3,685 shares, decreasing direct ownership by 0.74% to 496,939 units (SEC Form 4)4 - Vaxcyte, Inc. (0001649094) (Issuer)
- INSIDERSEC Form 4 filed by Vaxcyte Inc.4 - Vaxcyte, Inc. (0001649094) (Issuer)
- INSIDERSEC Form 4 filed by Vaxcyte Inc.4 - Vaxcyte, Inc. (0001649094) (Issuer)
- INSIDERSEC Form 4 filed by Vaxcyte Inc.4 - Vaxcyte, Inc. (0001649094) (Issuer)
- INSIDERSVP, Finance & CAO Cowan Elvia covered exercise/tax liability with 569 shares, was granted 10,681 shares and exercised 7,716 shares at a strike of $25.92, increasing direct ownership by 132% to 31,362 units (SEC Form 4)4 - Vaxcyte, Inc. (0001649094) (Issuer)
- INSIDERPRESIDENT AND CFO Guggenhime Andrew was granted 44,864 shares and covered exercise/tax liability with 1,907 shares, increasing direct ownership by 69% to 105,416 units (SEC Form 4)4 - Vaxcyte, Inc. (0001649094) (Issuer)
- INSIDERCHIEF EXECUTIVE OFFICER Pickering Grant covered exercise/tax liability with 5,394 shares and was granted 105,110 shares, increasing direct ownership by 25% to 500,624 units (SEC Form 4)4 - Vaxcyte, Inc. (0001649094) (Issuer)
- INSIDERChief Technical Ops Officer Dhaliwal Harpreet S. was granted 53,409 shares and covered exercise/tax liability with 757 shares, increasing direct ownership by 220% to 76,580 units (SEC Form 4)4 - Vaxcyte, Inc. (0001649094) (Issuer)
- INSIDERCHIEF OPERATING OFFICER Wassil Jim was granted 37,147 shares and covered exercise/tax liability with 3,807 shares, increasing direct ownership by 24% to 175,188 units (SEC Form 4)4 - Vaxcyte, Inc. (0001649094) (Issuer)
- SECSEC Form 8-K filed by Vaxcyte Inc.8-K - Vaxcyte, Inc. (0001649094) (Filer)
- SECSEC Form 424B5 filed by Vaxcyte Inc.424B5 - Vaxcyte, Inc. (0001649094) (Filer)
- SECSEC Form S-8 filed by Vaxcyte Inc.S-8 - Vaxcyte, Inc. (0001649094) (Filer)
- SECSEC Form 10-K filed by Vaxcyte Inc.10-K - Vaxcyte, Inc. (0001649094) (Filer)
- SECVaxcyte Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Vaxcyte, Inc. (0001649094) (Filer)